Further outcome data emerged for the thiazolidinedione rosiglitazone, which, again, highlighted the need for safety-focused CVOTs
GLP-1 Agonists Market Size, Share & Trends Analysis Report By Product (Branded GLP-1 Agonists, Dual / Triple, Biosimilars & Generic GLP-1 Agonists Agonists), By Indication (Type 2 Diabetes Mellitus, Obesity / Overweight Management, Cardiovascular & Metabolic Related Indications, Other Emerging Indications (e.g., NASH, Alzheimers-related)), By Route of Administration, By Distribution Channel, By Region and By Segments Forecasts, 2025-2034 GLP-1 Agonists Market Size is valued at USD 43.1 Bn in 2024 and is predicted to reach USD 260.1 Bn by the year 2034 at an 19.9% CAGR during the forecast period for 2025-2034
Cardiovasc Diabetol, 22
Choosing reliable suppliers is crucial, as purchasing from unverified sources can expose you to significant health risks, including counterfeit medications and compromised product quality
Strive Compounding Pharmacy received formal disciplinary action from the Arizona State Board of Pharmacy in February 2024 for improper semaglutide compounding and inaccurate compounding records, resulting in a $1,000 civil penalty
Some of the substances tested include alcohol, nicotine, cocaine, and opioids
